Literature DB >> 23318273

Effect of repeated exposure to MDMA on the function of the 5-HT transporter as assessed by synaptosomal 5-HT uptake.

Courtney Huff1, Nirmal Bhide, Allen Schroering, Bryan K Yamamoto, Gary A Gudelsky.   

Abstract

Recent studies have demonstrated that a preconditioning regimen (i.e., repeated low doses) of MDMA provides protection against the reductions in tissue concentrations of 5-HT and 5-HT transporter (SERT) density and/or expression produced by a subsequent binge regimen of MDMA. In the present study, the effects of preconditioning and binge treatment regimens of MDMA on SERT function were assessed by synaptosomal 5-HT uptake. Synaptosomal 5-HT uptake was reduced by 72% 7 days following the binge regimen (10 mg/kg, i.p. every 2 h for a total of 4 injections). In rats exposed to the preconditioning regimen of MDMA (daily treatment with 10 mg/kg for 4 days), the reduction in synaptosomal 5-HT uptake induced by a subsequent binge regimen was significantly less. Treatment with the preconditioning regimen alone resulted in a transient 46% reduction in 5-HT uptake that was evident 1 day, but not 7 days, following the last injection of MDMA. Furthermore, the preconditioning regimen of MDMA did not alter tissue concentrations of 5-HT, whereas the binge regimen of MDMA resulted in a long-term reduction of 40% of tissue 5-HT concentrations. The distribution of SERT immunoreactivity (ir) in membrane and endosomal fractions of the hippocampus also was evaluated following the preconditioning regimen of MDMA. There was no significant difference in the relative distribution of SERTir between these two compartments in control and preconditioned rats. The results demonstrate that SERT function is transiently reduced in response to a preconditioning regimen of MDMA, while long-term reductions in SERT function occur in response to a binge regimen of MDMA. Moreover, a preconditioning regimen of MDMA provides protection against the long-term reductions in SERT function evoked by a subsequent binge regimen of the drug. It is tempting to speculate that the neuroprotective effect of MDMA preconditioning results from a transient down-regulation in SERT function.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23318273      PMCID: PMC3578032          DOI: 10.1016/j.brainresbull.2013.01.003

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  34 in total

1.  Amphetamine and methamphetamine reduce striatal dopamine transporter function without concurrent dopamine transporter relocalization.

Authors:  Christopher L German; Glen R Hanson; Annette E Fleckenstein
Journal:  J Neurochem       Date:  2012-08-23       Impact factor: 5.372

2.  Loss of serotonin transporter protein after MDMA and other ring-substituted amphetamines.

Authors:  Tao Xie; Liqiong Tong; Michael W McLane; George Hatzidimitriou; Jie Yuan; Una McCann; George Ricaurte
Journal:  Neuropsychopharmacology       Date:  2006-01-25       Impact factor: 7.853

3.  Effect of ascorbate and cysteine on the 3,4-methylenedioxymethamphetamine-induced depletion of brain serotonin.

Authors:  G A Gudelsky
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

4.  Antagonists and substrates differentially regulate serotonin transporter cell surface expression in serotonergic neurons.

Authors:  Katharina Kittler; Thorsten Lau; Patrick Schloss
Journal:  Eur J Pharmacol       Date:  2009-12-16       Impact factor: 4.432

5.  Dopamine transporter down-regulation following repeated cocaine: implications for 3,4-methylenedioxymethamphetamine-induced acute effects and long-term neurotoxicity in mice.

Authors:  I Peraile; E Torres; A Mayado; M Izco; A Lopez-Jimenez; J A Lopez-Moreno; M I Colado; E O'Shea
Journal:  Br J Pharmacol       Date:  2009-12-10       Impact factor: 8.739

Review 6.  The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").

Authors:  A Richard Green; Annis O Mechan; J Martin Elliott; Esther O'Shea; M Isabel Colado
Journal:  Pharmacol Rev       Date:  2003-07-17       Impact factor: 25.468

7.  Differential long-term effects of MDMA on the serotoninergic system and hippocampal cell proliferation in 5-HTT knock-out vs. wild-type mice.

Authors:  Thibault Renoir; Eleni Païzanis; Malika El Yacoubi; Françoise Saurini; Naïma Hanoun; Maxette Melfort; Klaus Peter Lesch; Michel Hamon; Laurence Lanfumey
Journal:  Int J Neuropsychopharmacol       Date:  2008-07-09       Impact factor: 5.176

8.  Dynamic changes in vesicular glutamate transporter 1 function and expression related to methamphetamine-induced glutamate release.

Authors:  Karla A Mark; Maria S Quinton; Shelley J Russek; Bryan K Yamamoto
Journal:  J Neurosci       Date:  2007-06-20       Impact factor: 6.167

9.  The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain.

Authors:  D M Stone; D C Stahl; G R Hanson; J W Gibb
Journal:  Eur J Pharmacol       Date:  1986-08-22       Impact factor: 4.432

10.  The Nature of 3, 4-Methylenedioxymethamphetamine (MDMA)-Induced Serotonergic Dysfunction: Evidence for and Against the Neurodegeneration Hypothesis.

Authors:  Dominik K Biezonski; Jerrold S Meyer
Journal:  Curr Neuropharmacol       Date:  2011-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.